Nektar Therapeutics (NKTR)
43.58
-3.41
(-7.26%)
USD |
NASDAQ |
Oct 02, 16:00
43.40
-0.18
(-0.41%)
After-Hours: 20:00
Nektar Therapeutics Enterprise Value : 938.97M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 938.97M |
| October 01, 2026 | 1.055B |
| September 30, 2026 | 1.518B |
| September 29, 2026 | 1.473B |
| September 28, 2026 | 1.513B |
| September 25, 2026 | 1.399B |
| September 24, 2026 | 1.478B |
| September 23, 2026 | 1.420B |
| September 22, 2026 | 1.532B |
| September 21, 2026 | 1.733B |
| September 18, 2026 | 1.742B |
| September 17, 2026 | 1.785B |
| September 16, 2026 | 1.751B |
| September 15, 2026 | 1.726B |
| September 14, 2026 | 1.789B |
| September 11, 2026 | 1.832B |
| September 10, 2026 | 1.863B |
| September 09, 2026 | 1.954B |
| September 08, 2026 | 2.026B |
| September 04, 2026 | 1.984B |
| September 03, 2026 | 2.058B |
| September 02, 2026 | 1.934B |
| September 01, 2026 | 1.900B |
| August 31, 2026 | 1.888B |
| August 28, 2026 | 1.927B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.996B |
| August 26, 2026 | 1.969B |
| August 25, 2026 | 2.010B |
| August 24, 2026 | 1.967B |
| August 21, 2026 | 1.978B |
| August 20, 2026 | 1.995B |
| August 19, 2026 | 2.048B |
| August 18, 2026 | 1.965B |
| August 17, 2026 | 1.932B |
| August 14, 2026 | 1.944B |
| August 13, 2026 | 2.043B |
| August 12, 2026 | 2.046B |
| August 11, 2026 | 2.028B |
| August 10, 2026 | 2.007B |
| August 07, 2026 | 2.062B |
| August 06, 2026 | 1.958B |
| August 05, 2026 | 1.946B |
| August 04, 2026 | 1.935B |
| August 03, 2026 | 1.861B |
| July 31, 2026 | 1.864B |
| July 30, 2026 | 1.890B |
| July 29, 2026 | 1.864B |
| July 28, 2026 | 1.867B |
| July 27, 2026 | 1.887B |
| July 24, 2026 | 1.865B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.122T |
| Inovio Pharmaceuticals, Inc. | 66.84M |
| Tonix Pharmaceuticals Holding Corp. | -25.34M |
| Capricor Therapeutics, Inc. | 373.19M |
| Kyntra Bio, Inc. | -43.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.62M |
| Revenue (Quarterly) | 10.13M |
| Total Expenses (Quarterly) | 50.75M |
| EPS Diluted (Quarterly) | -1.229 |
| Gross Profit Margin (Quarterly) | 98.46% |
| Profit Margin (Quarterly) | -401.0% |
| Earnings Yield | -15.37% |
| Normalized Earnings Yield | -14.60 |